



Achillion Pharmaceuticals
Investor Relations Department
300 George St.
New Haven, CT 06511
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ACHN

Last Trade: 4.21

Trade Time: 4:00 PM ET
May 26, 2017

Change: 0.06 ↑ (+1.446%)

Day Range 4.13 - 4.32

52-Week Range 3.15 - 10.06

Volume 1,382,402

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 4, 2017

[Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs](#)

May 2, 2017

[Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference](#)

Apr 22, 2017

[Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178](#)

Apr 6, 2017

[Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria](#)

Mar 21, 2017

[USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors](#)

Financial Disclosures [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 23, 2017

[Annual Report \(10-K\)](#)

Apr 17, 2017

[Proxy Statement \(DEF 14A\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)